Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin
| Autor: | Wei Zhang, Guo-Qing Wang, Han-Suo Yang, Min Hu, Yan-jun Wen, Rui Wang, Yu Jiang, Xia Zhao, Xiaowei Zhang, Yu Quan Wei, Qiu-Ming He, Hong Xin Deng, Xiancheng Chen, Feng Peng, Jin Liang Yang, Ling Tian, Jiang Li |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cancer Research
Combination therapy Angiogenesis Antineoplastic Agents Apoptosis Pharmacology Metastasis Neovascularization Mice chemistry.chemical_compound In vivo In Situ Nick-End Labeling medicine Animals Fibrosarcoma Molecular Biology Cisplatin Mice Inbred BALB C business.industry Genetic Therapy Neoplasms Experimental medicine.disease Combined Modality Therapy Immunohistochemistry Vascular endothelial growth factor chemistry Molecular Medicine Female medicine.symptom business Cell Division Neoplasm Transplantation medicine.drug |
| Zdroj: | Cancer Gene Therapy. 13:940-947 |
| ISSN: | 1476-5500 0929-1903 |
| Popis: | Soluble Flk-1, a soluble vascular endothelial growth factor (VEGF) receptor, is a potent inhibitor of angiogenesis, which could restrain growth and metastasis of some experimental tumors. However, antiangiogenic agents alone cannot eradicate tumor completely, and should be combined with other therapy to enhance their effects. In this study, we evaluated the antitumor activity of the combination therapy in the immunocompetent BALB/c mice bearing H22 hepatoma and Meth A fibrosarcoma, respectively. Mice were treated with either msFlk-1 i.m. at 100 microg/mouse once every 3 days for four times from day 3 after the tumor cell injection, cisplatin cycled twice (2 mg/kg i.p. on days 4 and 11 after the tumor cell inoculation), or both agents together. Tumor growth and survival time were continually observed. Antiangiogenesis in vivo was determined by CD31 immunohistochemistry. Assessment of apoptotic cells and histological analysis was also conducted in tumor tissues. Our results showed that the combination therapy could evidently improve antitumor efficacy, including tumor growth suppression, mice survival prolongation, tumor cell apoptosis augmentation as well as neovascularization inhibition as compared with controls, without serious adverse effects. Our data suggest that the combination of DDP with msFlk-1 is more effective to suppress tumor growth in mice than either agent alone, and this combination regimen showed its potential for future clinical application. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|